Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Resistance news

Show

From To
A Mysterious Infection, Spanning the Globe in a Climate of Secrecy

The rise of Candida auris embodies a serious and growing public health threat: drug-resistant germs. Over the last five years, it has hit a neonatal unit in Venezuela, swept through a hospital in Spain, forced a prestigious British medical center to shut down its intensive care unit, and taken root in India, Pakistan and South Africa.

Published
08 April 2019
From
New York Times
Dolutegravir-based second-line ART achieves excellent virological outcomes even in the presence of resistance to recycled NRTIs

Virological response rates were excellent among patients receiving second-line antiretroviral therapy (ART) based on dolutegravir, even when regimens included a nucleoside/nucleotide reverse transcriptase inhibitor (NRTI) to which there

Published
13 March 2019
By
Michael Carter
Can high-dose dolutegravir be a rescue therapy?

A small study in Italy found that high doses of the powerful integrase inhibitor dolutegravir (Tivicay, and also found in Juluca and Triumeq) can be used as a key part of rescue therapy for people with HIV that has extensive drug resistance to treatment. When doctors doubled the dose typically prescribed for treatment-experienced people to 100 mg twice daily, they found that high-dose dolutegravir was well absorbed with no occurrence of neuropsychiatric or serious side effects.

Published
12 March 2019
From
CATIE
One in six South Africans drug resistant before starting HIV treatment

One in six people not on treatment in a large South African household survey already had drug-resistant HIV and more than half of those on treatment had

Published
11 March 2019
By
Keith Alcorn
How many people who have used PrEP get HIV the same year? New York study finds out

One question often asked about pre-exposure prophylaxis (PrEP) use is how frequently people start PrEP while unknowingly having HIV, often because they have acquired it so recently

Published
07 March 2019
By
Gus Cairns
South Africa reports successful third-line HIV treatment programme

People with resistance to first- and second-line antiretroviral drugs can still achieve high rates of viral suppression in the first year on third-line regimens according to a

Published
04 January 2019
By
Esther Nakkazi
Should we be concerned some gay men are buying antibiotics online for STIs?

A leading online provider of PrEP also sells the antibiotic doxycycline - but why are people buying it and why are health organizations concerned?

Published
28 December 2018
From
Gay Star News
Resistance to second-line ARTs increasing in South Africa

An increasing number of HIV patients in the Western Cape and other parts of South Africa are experiencing resistance to second-line antiretroviral therapy (ART). The Star reports that this was revealed by the fifth South African National HIV Prevalence, Incidence, Behaviour and Communication Survey conducted last year by the Human Sciences Research Council (HSRC). The survey found resistance to ARVs in 27.4% of the respondents who were not virally suppressed.

Published
14 December 2018
From
Medical Brief
How dangerous is gonorrhoea resistance and can it be halted?

The bacterium that causes the common sexually transmitted infection (STI) gonorrhoea develops resistance to antibiotics easily, and some cases of multidrug-resistant gonorrhoea, originating from abroad, were reported

Published
06 December 2018
By
Gus Cairns
Fostemsavir, novel gp120 inhibitor, salvages nearly half of people with no other treatment options left

The recent International Congress on Drug Therapy in HIV Infection (HIV Glasgow) featured trials of several HIV drugs with modes of action different from the usual

Published
07 November 2018
By
Gus Cairns
← First12345...39Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.